Premium
Inactivation of mycoplasma species in blood by INACTINE PEN110 process
Author(s) -
Zavizion Boris,
Purmal Andrei,
Chapman John,
Alford Bernadette
Publication year - 2004
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2004.00647.x
Subject(s) - mycoplasma , mycoplasma pneumoniae , incubation , pathogen , incubation period , titer , mycoplasmataceae , microbiology and biotechnology , biology , mollicutes , immunology , medicine , pneumonia , biochemistry , antibody
BACKGROUND: Mycoplasmas have been associated with multiple acute and chronic diseases. Mycoplasma genome is found in the blood of 10 to 15 percent of subjectively healthy individuals. If blood borne and viable in donated blood, mycoplasmas could potentially be transfusion transmissible. The INACTINE PEN110 technology is a pathogen reduction process that is in Phase 3 clinical studies. The present study investigated the ability of this process to eradicate mycoplasmas in human blood. STUDY DESIGN AND METHODS: Identical whole blood or RBC units inoculated with Mycoplasma arthritidis or M. pneumoniae were incubated with PEN110 (inactivating agent) for 24 hours at 23°C. Sham controls were treated with buffer under the same conditions. 4°C controls were put on storage immediately after the spike. RESULTS: No viable microorganisms were detected in PEN110‐treated units after 24 hours of incubation. Sham controls showed no changes to mycoplasma titers during the incubation. In 4°C controls, minor decrease of mycoplasma titers was observed during the storage. CONCLUSION: The INACTINE process inactivates more than 10 7 mycoplasma CFU per mL in whole blood and RBCs. This study is the first demonstration of susceptibility of mycoplasmas to pathogen reduction. The data provide further support for the ability of INACTINE technology to address microbial safety issues that are not well characterized.